Prognostic nomogram for diffuse large <scp>B</scp>‐cell lymphoma incorporating the International Prognostic Index with interim‐positron emission tomography findings

Chow, Alyssa; Phillips, Michael; Siew, Teck; Cull, Gavin; Augustson, Bradley; Ward, Mitchell Steven; Joske, David

doi:10.1111/imj.12194

Cited by 13 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A nomogram integrates different clinical variables to provide an individualized prognosis assessment, which shows more benefits contrasted to current prognostic systems in several clinical settings [22–24]. In accordance with previous studies, our nomogram made a more favorable and detailed prediction of OS than the current prognostic systems.…”

Section: Discussionsupporting

confidence: 80%

Prognostic nomogram for previously untreated adult patients with acute myeloid leukemia

Zheng

Zhu

et al. 2016

Oncotarget

View full text Add to dashboard Cite

This study was designed to perform an acceptable prognostic nomogram for acute myeloid leukemia. The clinical data from 311 patients from our institution and 165 patients generated with Cancer Genome Atlas Research Network were reviewed. A prognostic nomogram was designed according to the Cox's proportional hazard model to predict overall survival (OS). To compare the capacity of the nomogram with that of the current prognostic system, the concordance index (C-index) was used to validate the accuracy as well as the calibration curve. The nomogram included 6 valuable variables: age, risk stratifications based on cytogenetic abnormalities, status of FLT3-ITD mutation, status of NPM1 mutation, expression of CD34, and expression of HLA-DR. The C-indexes were 0.71 and 0.68 in the primary and validation cohort respectively, which were superior to the predictive capacity of the current prognostic systems in both cohorts. The nomogram allowed both patients with acute myeloid leukemia and physicians to make prediction of OS individually prior to treatment.

show abstract

Section: Discussionsupporting

confidence: 80%

Prognostic nomogram for previously untreated adult patients with acute myeloid leukemia

Zheng

Zhu

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…A nomogram is a visual format of a statistical predictive model that permits improved predictive accuracy for clinical outcomes compared with the former prognostic scales through calculating the cumulative effect of each independent variable [23]. A wide variety of nomograms were previously developed for malignacies and some were indicated for DLBCL [18,19,[24][25][26][27][28][29][30], incorporating clinicopathological parameters to predict the survival of patients ( Supplementary Table). Although some of these nomograms were dedicated to incorporating NLR and inflammatory cytokines into nomogram construction for accurate survival prediction [28][29][30], they were all indicated for de novo patients with front-line treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Although some of these nomograms were dedicated to incorporating NLR and inflammatory cytokines into nomogram construction for accurate survival prediction [28][29][30], they were all indicated for de novo patients with front-line treatment. Furthermore, some of the above mentioned DLBCL-specific nomograms have not yet been validated in an external cohort [28]. Additionally, a nomogram previously proposed based on r/r DLBCL in our center included patients in the pre-and post-rituximab era, without treatment information in the second-line setting.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens

et al. 2020

View full text Add to dashboard Cite

Background:The clinical course of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) is variable, with limited efficacy data of second-line treatment in a post-rituximab real-world context. Hence, we explored the predictors and constructed a nomogram for risk stratification in this population. Patients and methods: Among 296 r/r DLBCL patients pretreated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) at the Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College between 2006 and 2017, 231 were included for nomogram construction. After randomization, we constructed the prognostic nomogram in the primary cohort (n=161) based on a multivariate analysis and confirmed it in the validation cohort (n=70). Additionally, we explored predictive factors for second-line therapy using a ordinal regression analysis. Results: Four independent prognostic factors including rituximab in the second-line setting, initial Eastern Cooperative Oncology Group (ECOG) performance status (PS), response to front-line treatment, and invasion on progression/recurrence were used to construct the nomogram. The nomogram had a C index of 0.70 with AUC values of 0.73 and 0.71 for the primary and validation cohorts, respectively. Subsequently, three risk groups (low, intermediate, and high) were determined with median overall survival (OS) of 38.0, 25.0, and 7.0 months, respectively. Additionally, we conducted a multivariate ordinal regression analysis and identified prior response to front-line treatment (odds ratio=4.50, 95% CI: 1.84-11.27, p=0.001) and bulky disease at diagnosis (odds ratio=0.36, 95% CI: 0.182-0.702, p=0.003) were two independent factors for second-line treatment efficacy. Conclusions: The established predictors for treatment efficacy and the novel nomogram for survival in r/r DLBCL patients could potentially be applied for risk stratification and treatment guidance in the post-rituximab era.

show abstract

“…In a simplified way, prognostic factors of tumors can be classified into disease-related factors, host-related factors, and treatment-related factors. As in the retrospective study by Chow et al [35] involving 76 DLBCL patients, the prognostic accuracy for PFS of PET result was limited(C=0.63), as it was for IPI (C=0.75). However, with the two indicators combined, the predictive accuracy was improved(C=0.81).…”

Section: Discussionmentioning

confidence: 89%

Clinical Features and Prognosis Analysis of Hodgkin Lymphoma: A Multicenter Retrospective Study Over a Decade of Patients in China

Geng

Hao³

et al. 2017

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

show abstract

Prognostic nomogram for diffuse large B‐cell lymphoma incorporating the International Prognostic Index with interim‐positron emission tomography findings

Abstract: In DLBCL patients treated with immunochemotherapy, the IPI and interim-PET provide independent prognostic information. In combination, a more powerful predictive model may be created as a nomogram. This can be refined in prospective trials and may help clinical decision making.

Cited by 13 publications

References 19 publications

Prognostic nomogram for previously untreated adult patients with acute myeloid leukemia

Prognostic nomogram for previously untreated adult patients with acute myeloid leukemia

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens

Clinical Features and Prognosis Analysis of Hodgkin Lymphoma: A Multicenter Retrospective Study Over a Decade of Patients in China

Contact Info

Product

Resources

About